Objective
The client was one of the top biopharmaceutical companies, seeking to comprehend patient dynamics in terms of patient share and overall market access for the biosimilar version of Remicade. The study aimed to develop a Budget Impact Analysis model for the biosimilar version of Infliximab (Remsima), which was under process approval for treating rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis in five European countries (Germany, UK, Italy, Netherlands, and Belgium). The client desired an estimation of the Remicade-treated patient pool and the calculation of the share of switch and naive patient pools from Remicade to Remsima.
Additionally, a scenario-based comparison of the annual cost of therapy for both Remicade and Remsima (Remsima launched at discounts of 10%, 20%, & 30% compared to Remicade) was conducted to evaluate the overall impact of Remsima’s launch on the disease burden and patient access at each country level.
Approach
The study approach involves a comprehensive secondary research strategy, incorporating an extensive review of various data sources such as publications, journals, registries, trial registries, and other public domains. This involves an in-depth examination of existing literature through literature reviews and meta-analysis. The foundation of the budget impact analysis model has been laid through this rigorous secondary research process to ensures a comprehensive understanding of the patient dynamics, market access, and budget implications associated with the introduction of the biosimilar Remsima in the specified European countries. The utilization of rigorous secondary research methods and the incorporation of key elements in the budget impact model contribute to the robustness and reliability of the study’s findings.
Results
The key components of the budget impact analysis model included:
Epidemiology Analysis: Investigated both the incidence and prevalence of the focused medical indications across the target populations in the specified European countries
Patient Share Analysis: Identified and assessed the patient share for Remsima, considering both naive patients and those who switch from Remicade. The focus is on determining the peak patient share for Remsima.
Annual Cost of Therapy Calculation: Developed a robust calculation for the annual cost of therapy. This involves a careful analysis based on the dose and days of therapy required for patients
Scenario-based Analysis: Considering various scenarios, particularly the impact of Remsima’s launch at different discount rates (10%, 20%, and 30%) in comparison to Remicade, evaluated the potential changes in patient access and disease burden under varying pricing scenarios.
Country-level Assessment: Evaluated the total number of patients to be benefited at each country level by thorough examination of patient pools in Germany, UK, Italy, Netherlands, and Belgium, factoring in the different discount rates for Remsima.
